She has built a reputation as one of the most powerful and influential lawyers in the world but Pfizer has confirmed that its high-profile general counsel and executive leadership member Amy Schulman is to leave the pharma giant just weeks before the in-house lawyer was due to take up a new post.
Schulman had joined Pfizer in 2008 from her position as co-head of mass tort and class actions at DLA Piper. The star litigator, who was reportedly responsible for a $60m book of business, was an equally high-profile general counsel going on to pioneer the Pfizer Legal Alliance, a radical attempt to usher in annually fixed fees for advisers that entirely ditched the billable hour.
The move comes despite Schulman in July being named as head of vaccines, oncology and consumer healthcare business, a post she was expected to assume in the New Year.